Satureja hortensis induces cell death and inhibited cell cycle progression in K562 myelogenous and Jurkat T cell leukemia cell lines.
Satureja hortensis induces cell death and inhibited cell cycle progression in K562 myelogenous and Jurkat T cell leukemia cell lines. J Immunoassay Immunochem. 2019 Jun 17;:1-14 Authors: Asadipour M, Amirghofran Z Abstract Several plants of Satureja genus have shown anti-tumor activity. We investigated the antileukemia effects of different fractions of Satureja hortensis (Summer savory). The growth inhibitory effect of S. hortensis fractions on K562 and Jurkat leukemia cells were determined by MTT assay. The most effective fractions were analyzed by flow cytometry and colorimetric assay for apoptosis induction and cell cycle changes. Various fractions from S. hortensis showed growth inhibitory effects on leukemia cells, among them two hexane and dichloromethane fractions with IC50 values of 32.1-47.8 μg/ml (K562) and 44.3-45.7 μg/ml (Jurkat) were the most effective. According to annexin V staining, both of these fractions significantly induced apoptosis at 50μg/ml in K562 (hexane; 73.06 ± 5.11% and dichloromethane; 96.14 ± 2.33%) and Jurkat cells (hexane; 78.85 ± 11.9% and dichloromethane; 94.05 ± 2.47%) 48 h after treatment. They increased cell accumulation in sub-G1 phase (>50%, p
CONCLUSION: Our results showed increased percentages of regulatory T cells in pediatric ALL patients despite chemotherapy, which might be compromising the anti-leukemic cellular immune response. PMID: 32224544 [PubMed - in process]
CONCLUSION: In conclusion, we have shown that an increased percentage of M-MDSC cells producing IL-10 and TGF-β1 in CLL patients may be associated with the suppression of the immune response against CLL. It can be assumed that the increased percentage of M-MDSC with an intracellular expression of IL-10 and TGF-β1 may be used in the future as the factor defining the group of patients with shorter time to onset of treatment. PMID: 32227331 [PubMed - as supplied by publisher]
Authors: Miyoshi I, Mori M, Yamasaki I, Daibata M PMID: 32224562 [PubMed - in process]
Contributors : Ling Li ; Xin HeSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe want to obtain FLT3-ITD gene signature. To do so, we transduced CB CD34+ cells with mock or FLT3-ITD vectors and performed RNA sequencing (RNA-Seq).Two Groups: Group1: CB CD34+ cells transduced with mock vector; Group2: CB CD34+ cells transduced with FLT3-ITD vector;
Contributors : Elizabeth Ostrander ; Grant A ChallenSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusEpigenetic modifying enzymes DNMT3A and TET2 are recurrently mutated in hematological disorders despite possessing opposing biochemical functions in the DNA methylation processes. Using conditional ablation, we show these contrasting genotypes result in different functional effects in hematopoietic stem cells (HSCs). Loss of Dnmt3a bestows enhanced self-renewal on HSCs in serial, competitive repopulation assays while Tet...
Publication date: Available online 31 March 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Nada Alhazmi, Chun-Peng Pai, Aljawharah Albaqami, Han Wang, Xuan Zhao, Minyue Chen, Po Hu, Shuang Guo, Kyle Starost, Omid Hajihassani, Masaru Miyagi, Hung-Ying Kao
A 34-year-old man with chronic myelogenous leukemia status post allogeneic hematopoietic stem cell transplant (HSCT) on tacrolimus for graft-vs-host disease prophylaxis, presented with a 1-week history of fevers and severe headaches. Brain magnetic resonance imaging (MRI) demonstrated numerous small focal lesions in the left basal ganglia and left temporal lobe with a ring pattern, as well as a large lesion in the left occipital lobe with mild leptomeningeal enhancement (Figure 1). Cerebrospinal fluid (CSF) analysis revealed lymphocytic pleocytosis, and Toxoplasma gondii was detected by polymerase chain reaction (PCR).
Conditions: Acute Leukemia; Myelodysplastic Syndromes Intervention: Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells Sponsor: Edwin Horwitz Not yet recruiting
A new combination of old drugs has shown'unexpectedly'higher response rates in patients with relapsed/refractory acute myeloid leukemia.Medscape Medical News
Publication date: Available online 30 March 2020Source: The Veterinary JournalAuthor(s): Y.C. Chen, C.C. Chang, W.L. Hsu, S.T. Chuang